Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00027872 · ClinicalTrials.gov registry record · Phase 2
Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 125
- Enrollment target
NCT00027872: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00027872 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 125 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00027872, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 125 participants
- Enrollment target
Study Summary
Tipifarnib may stop the growth of cancer cells by blocking the enzymes necessary for their growth. Phase II trial to study the effectiveness of tipifarnib in treating older patients who have previously untreated acute myeloid leukemia
Primary Outcome
CR rates will be calculated with 95% confidence intervals for each age group separately.
Interventions
- OTHER laboratory biomarker analysis
- DRUG tipifarnib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2001-10 |
| Est. Completion | 2009-01 |
| Phase | Phase 2 |
What the finished NCT00027872 record still lists
NCT00027872 is an interventional study that assigns participants to a tested intervention. The registered 125 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT00027872 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00027872 about?
NCT00027872 is a clinical study titled "Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia". Tipifarnib may stop the growth of cancer cells by blocking the enzymes necessary for their growth. Phase II trial to study the effectiveness of tipifarnib in treating older patients who have previously untreated acute myeloid leukemia
What is the current status of trial NCT00027872?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 125 participants. The study started on 2001-10. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00027872?
The interventions under investigation include: laboratory biomarker analysis (OTHER), tipifarnib (DRUG).
Who is sponsoring clinical trial NCT00027872?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00027872's enrollment target sits among peer trials
125 558th of 2000 higher than 1,437 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02717039 · 125 participants
Pharmacogenomics of Heparin-Induced Thrombocytopenia
- NCT02763033 · 125 participants · Phase 2
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
- NCT02793999 · 125 participants
Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia
- NCT03003299 · 125 participants · NA
PARTNER 3 Trial - Aortic Valve-in-Valve
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia